Virax Biolabs Group Limited

VRAX59

Penny Stock

$1.81arrow_drop_down6.64%-$0.12

Penny Stock

VRAX59

$1.81

arrow_drop_down6.64%-$0.12

Penny Stock

Performance History

Key Stats
Open	$1.98
Prev. Close	$1.92
EPS	-3.36
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$8.16M
PE Ratio	-

	LOW	HIGH
Day Range	1.78	1.92
52 Week Range	0.60	9.00

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-3.36

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Virax Biolabs Group Limited (VRAX)

Virax Biolabs Group Limited (VRAX) is a biotechnology company that focuses on research and development of innovative therapeutics and diagnostic tools for the treatment and prevention of infectious diseases. The company is dedicated to improving global health by addressing the challenges posed by emerging pathogens and the increasing threat of antimicrobial resistance.

With a strong team of scientists and experts in the field, Virax Biolabs Group Limited is at the forefront of developing cutting-edge solutions to combat infectious diseases. The company's product portfolio includes novel antiviral drugs, diagnostic assays, and therapeutic antibodies. These products are designed to effectively target and eliminate a wide range of viral infections, including respiratory viruses, HIV, and hepatitis.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. James Foster
Headquarters: London
Employees: 11
Exchange: NASDAQ

add Virax Biolabs Group Limited to watchlist

Keep an eye on Virax Biolabs Group Limited

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Virax Biolabs Group Limited's (VRAX) price per share?

The current price per share for Virax Biolabs Group Limited (VRAX) is $1.81. The stock has seen a price change of -$0.13 recently, indicating a -6.65% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Virax Biolabs Group Limited (VRAX)?

For Virax Biolabs Group Limited (VRAX), the 52-week high is $9, which is 396.96% from the current price. The 52-week low is $0.6, the current price is 201.83% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Virax Biolabs Group Limited (VRAX) a growth stock?

Virax Biolabs Group Limited (VRAX) has shown an average price growth of -7.23% over the past three years. It has received a score of 97 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Virax Biolabs Group Limited as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Virax Biolabs Group Limited (VRAX) stock price performance year to date (YTD)?

As of the latest data, Virax Biolabs Group Limited (VRAX) has a year-to-date price change of 32.19%. Over the past month, the stock has experienced a price change of 11.1%. Over the last three months, the change has been -71.7%. Over the past six months, the figure is 128.92%.

help

Is Virax Biolabs Group Limited (VRAX) a profitable company?

Virax Biolabs Group Limited (VRAX) has a net income of -$6.74M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 32.34% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -4.25K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $50.59K. Operating income is noted at -$6.5M. Furthermore, the EBITDA is -$6.05M.

help

What is the market capitalization of Virax Biolabs Group Limited (VRAX)?

Virax Biolabs Group Limited (VRAX) has a market capitalization of $8.42M. The average daily trading volume is 1.89, indicating the stock's liquidity and investor engagement.

News

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

Why LQR House Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket

NEWS

PENNY STOCKS

SMALL CAP